DK3275883T3 - Fremgangsmåde til produktion af ny nitrogenholdig forbindelse eller salt deraf, og mellemprodukt deraf - Google Patents

Fremgangsmåde til produktion af ny nitrogenholdig forbindelse eller salt deraf, og mellemprodukt deraf Download PDF

Info

Publication number
DK3275883T3
DK3275883T3 DK16768957.9T DK16768957T DK3275883T3 DK 3275883 T3 DK3275883 T3 DK 3275883T3 DK 16768957 T DK16768957 T DK 16768957T DK 3275883 T3 DK3275883 T3 DK 3275883T3
Authority
DK
Denmark
Prior art keywords
salts
procedure
production
containing composition
intermediate products
Prior art date
Application number
DK16768957.9T
Other languages
English (en)
Inventor
Hirofumi Fukunaga
Sachiko Shinjo
Daisuke Nakagawa
Shinichiro Sekine
Takayuki Yamakawa
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Application granted granted Critical
Publication of DK3275883T3 publication Critical patent/DK3275883T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D255/00Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic System
    • C07F1/005Compounds containing elements of Groups 1 or 11 of the Periodic System without C-Metal linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic System
    • C07F1/08Copper compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/003Compounds containing elements of Groups 3 or 13 of the Periodic System without C-Metal linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DK16768957.9T 2015-03-25 2016-03-25 Fremgangsmåde til produktion af ny nitrogenholdig forbindelse eller salt deraf, og mellemprodukt deraf DK3275883T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015062306 2015-03-25
PCT/JP2016/059729 WO2016153054A1 (ja) 2015-03-25 2016-03-25 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体

Publications (1)

Publication Number Publication Date
DK3275883T3 true DK3275883T3 (da) 2021-06-28

Family

ID=56977546

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16768957.9T DK3275883T3 (da) 2015-03-25 2016-03-25 Fremgangsmåde til produktion af ny nitrogenholdig forbindelse eller salt deraf, og mellemprodukt deraf

Country Status (24)

Country Link
US (3) US20180008583A1 (da)
EP (3) EP3275883B1 (da)
JP (1) JP6411634B2 (da)
KR (1) KR102029746B1 (da)
CN (2) CN107428755B (da)
AU (4) AU2016237099C1 (da)
BR (1) BR112017020484B1 (da)
CA (1) CA2980268C (da)
CO (1) CO2017010806A2 (da)
CY (1) CY1124387T1 (da)
DK (1) DK3275883T3 (da)
ES (1) ES2877707T3 (da)
HR (1) HRP20211031T1 (da)
HU (1) HUE059670T2 (da)
IL (4) IL254532B (da)
LT (1) LT3275883T (da)
MX (3) MX2017012184A (da)
PL (1) PL3275883T3 (da)
PT (1) PT3275883T (da)
RS (1) RS62165B1 (da)
RU (2) RU2720989C2 (da)
SG (2) SG10201902609TA (da)
SI (1) SI3275883T1 (da)
WO (1) WO2016153054A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3929196T3 (pl) 2013-09-24 2023-12-11 Fujifilm Corporation Kompozycja farmaceutyczna związku zawierającego atom azotu lub jego soli, lub ich kompleksu z metalem
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
BR112019017929A2 (pt) 2017-02-28 2020-05-19 Morphic Therapeutic Inc inibidores de integrina (alfa-v)(beta-6)
CR20210109A (es) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBICIÓN DE LA INTEGRINA av ß6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CN113853220A (zh) * 2019-03-11 2021-12-28 生物相容英国有限公司 用于中枢神经***肿瘤治疗的放射性微球
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
EP4262886A1 (en) 2020-12-21 2023-10-25 Advanced Accelerator Applications International S.A. Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5941386B2 (ja) 1977-01-14 1984-10-06 株式会社紀文 高蛋白水産練製品様食品の製法
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
AU5362998A (en) 1996-11-27 1998-06-22 Du Pont Pharmaceuticals Company Novel integrin receptor antagonists
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
WO1999031061A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
EP1140204A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
PT1140203E (pt) * 1998-12-18 2007-08-30 Bristol Myers Squibb Pharma Co Medicamentos antagonistas do receptor da vitronectina
WO2001053262A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU7002501A (en) * 2000-06-21 2002-01-02 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
ES2376161T3 (es) 2001-01-29 2012-03-09 Janssen Pharmaceuticals, Inc. Indoles sustituidos y su utilización como antagonistas de integrinas.
KR101383655B1 (ko) 2010-05-24 2014-04-10 주식회사 바이오이미징코리아 트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물
FR2968999B1 (fr) * 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) * 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
WO2013048996A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Method for the purification of a peptide-based imaging agent precursor
LT2840080T (lt) * 2012-04-17 2018-02-12 Fujifilm Corporation Heterociklinis junginys, turintis azotą, arba jo druska
FR3001154B1 (fr) * 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
PL3929196T3 (pl) * 2013-09-24 2023-12-11 Fujifilm Corporation Kompozycja farmaceutyczna związku zawierającego atom azotu lub jego soli, lub ich kompleksu z metalem

Also Published As

Publication number Publication date
IL254532A0 (en) 2017-11-30
IL283224A (en) 2021-07-29
KR20170117577A (ko) 2017-10-23
EP3275883A1 (en) 2018-01-31
JP6411634B2 (ja) 2018-10-24
CN111171026B (zh) 2023-03-03
AU2016237099B2 (en) 2019-11-07
WO2016153054A1 (ja) 2016-09-29
AU2019246859A1 (en) 2019-10-31
CN107428755B (zh) 2020-03-03
IL254532B (en) 2021-12-01
US20210015802A1 (en) 2021-01-21
RU2017133107A3 (da) 2019-04-25
CO2017010806A2 (es) 2018-01-16
AU2019246859B2 (en) 2020-07-02
CN111171026A (zh) 2020-05-19
US20240108607A1 (en) 2024-04-04
RU2017133107A (ru) 2019-04-25
SG11201707899SA (en) 2017-10-30
RU2720989C2 (ru) 2020-05-15
AU2016237099C1 (en) 2023-01-19
BR112017020484A2 (pt) 2018-07-03
LT3275883T (lt) 2021-08-25
IL283288B (en) 2022-02-01
MX2023005703A (es) 2023-05-29
IL283289A (en) 2021-07-29
PT3275883T (pt) 2021-07-07
HUE059670T2 (hu) 2022-12-28
IL283289B (en) 2022-02-01
AU2016237099A1 (en) 2017-10-19
HRP20211031T1 (hr) 2021-10-01
CA2980268C (en) 2021-10-26
ES2877707T3 (es) 2021-11-17
EP3275883B1 (en) 2021-06-02
KR102029746B1 (ko) 2019-10-08
SG10201902609TA (en) 2019-04-29
EP3872079A1 (en) 2021-09-01
PL3275883T3 (pl) 2021-11-15
MX2023005704A (es) 2023-05-29
AU2020244580B2 (en) 2022-08-11
CN107428755A (zh) 2017-12-01
CA2980268A1 (en) 2016-09-29
RU2767398C2 (ru) 2022-03-17
MX2017012184A (es) 2018-01-09
RS62165B1 (sr) 2021-08-31
IL283224B (en) 2022-02-01
AU2020244578B2 (en) 2022-08-11
BR112017020484B1 (pt) 2023-03-28
EP3275883A4 (en) 2018-03-07
AU2020244578A1 (en) 2020-11-05
US20180008583A1 (en) 2018-01-11
IL283288A (en) 2021-07-29
RU2020115068A (ru) 2020-06-26
EP4059936A1 (en) 2022-09-21
JPWO2016153054A1 (ja) 2018-04-19
CY1124387T1 (el) 2022-07-22
AU2020244580A1 (en) 2020-11-05
RU2020115068A3 (da) 2020-08-17
SI3275883T1 (sl) 2021-09-30

Similar Documents

Publication Publication Date Title
DK3287445T3 (da) Pyrazolonforbindelse eller salt deraf, fremstillingsfremgangmåde dertil, herbicidsammensætning og anvendelse deraf
DK3283435T3 (da) Sammensætning, partikelformede materialer og fremgangsmåder til fremstilling af partikelformede materialer
DK3275883T3 (da) Fremgangsmåde til produktion af ny nitrogenholdig forbindelse eller salt deraf, og mellemprodukt deraf
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3283470T3 (da) Processer til fremstilling af 2,5-furandicarboxylsyre og derivater deraf
HK1251546A1 (zh) S-***的(s)-csa鹽、s-***的(r)-csa鹽和用於製備s-***的方法
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3355329T3 (da) Metode til fremstilling af lithium-ion-kondensator og kondensator som opnås med den nævnte metode
DK3341355T3 (da) (s)-3-amino-4-(difluormethylenyl)cyclopent-1-en-1-carboxylsyre og tilhørende forbindelser som gaba-aminotransferaseinaktivatorer til behandling af epilepsi, afhængighed og hepatocellulært karcinom
DK3408326T3 (da) Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
DK3337853T3 (da) Polyethylensammensætninger, fremgangsmåde og låg
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3424924T3 (da) Ureaforbindelse, fremgangsmåde til fremstilling deraf og medicinsk anvendelse deraf
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3307675T3 (da) Multi-tryk-fremgangsmåde til fremstilling af ammoniak
DK3412671T3 (da) TLR7-agonist-maleatsalt, krystallinske former C, D og E deraf, fremgangsmåder til fremstilling og anvendelser af maleatsalt og krystallinske former
DK3429998T3 (da) Fremgangsmåde til fremstilling af quinolin-2-yl-phenylaminderivater og disses salte
DK3265443T3 (da) Pyrrolidincarboxamidderivater og fremgangsmåde til fremstilling og anvendelse af samme
DK3750893T3 (da) Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf
DK3315181T3 (da) Sammensat emne og fremgangsmåde til at fremstille samme
DK3275454T3 (da) Farmaceutisk sammensætning med silybin, ve og l-carnitin
DK3110837T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf